Patient leaflet - Hemabate Sterile solution
1. What Hemabate Sterile Solution is and what it is used for
Therapeutic group*
This medicine contains carboprost tromethamine, which belongs to a group of medicines called prostaglandins. Prostaglandins are produced naturally in your body and are very important for a variety of activities, including childbirth. After
childbirth they make the womb contract and to help it stay contracted, which stops heavy bleeding from the womb. Hemabate given after childbirth increases the contraction of your womb which helps to control bleeding after delivery. Therapeutic indications
- Hemabate is a sterile solution for injection. It is available in ampoules and contains 250 mcg of the active ingredient, carboprost, per ml of solution.
- Hemabate is used to stop excessive bleeding in women who have just given birth, when bleeding is due to the womb failing to return to its normal size. * A therapeutic group is one in which a drug is classified depending on its actions and the part(s) of the body it affects.
2. What you need to know before you are given Hemabate Sterile Solution
Do not take Hemabate
Hemabate is not suitable for all women. Your doctor may decide to give you a different medicine if any of these apply to you. You should not be given Hemabate
if you are allergic to carboprost tromethamine or to any of the other ingredients of this medicine listed in section 6, in particular benzyl alcohol which can cause problems in some people – see section 4 of this leaflet for more details.
- if you currently have an infection of your womb, ovaries or fallopian tubes (this may be causing pain in your pelvis or vaginal discharge).
- if you have any problems with your heart, lung, kidney or liver.
if you are pregnant.
Warnings and precautions
Talk to your doctor or nurse before you are given Hemabate if you currently have, or have had in the past any of the following, as Hemabate will have to be used more carefully;
- lung disease, including asthma
- high or low blood pressure (including high blood pressure in pregnancy)
- heart disease or anaemia (low blood count)
- kidney or liver disease (including jaundice)
- glaucoma (raised pressure in your eyes)
- diabetes or epilepsy
- a caesarean section or any other operation on your womb
In very rare cases heart and circulation failure have been reported following the use of prostaglandins (the active ingredient of this medicine).
It is possible that this medicine may lower the oxygen levels in your blood. If you have previously suffered from conditions affecting your heart and lungs your doctor will monitor you and may give you additional oxygen as necessary.
Your doctor may give you other medicines to reduce the side effects of being sick or having diarrhoea as these are the common side effects of all prostaglandins (the active ingredient of this medicine).
Raised temperature has been observed with treatment from Hemabate. This will usually return to normal several hours after the last injection.
Other medicines and Hemabate
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
Treatments that strengthen contraction of the womb, including oxytocin and ergometrine, can be affected by Hemabate. Medical staff will watch over you very carefully if you have had these treatments as well as Hemabate.
Pregnancy, breast-feeding and fertility
Hemabate will only be given shortly after you have delivered your baby and not while you are still pregnant as it could put the embryo or foetus at risk.
It is not known if carboprost is excreted in human breast milk. As your own body produces prostaglandins during childbirth, Hemabate is not expected to cause any harm to your baby.
It is not known what effects Hemabate has on your fertility.
Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines
Do not drive, use any tools or operate machinery soon after receiving Hemabate as it may affect your ability to do so safely. Hemabate may make you lose consciousness, feel dizzy or drowsy.
Hemabate contains sodium and benzyl alcohol.
This medicine contains less than 1 mmol sodium (23 mg) per ml of solution, that is to say essentially ‘sodium‑free’. This medicine contains 9.45 mg benzyl alcohol in each ampoule which is equivalent to 9.45 mg/ml. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called “gasping syndrome”) in young children.
Ask your doctor or pharmacist for advice if you are pregnant or breast‑feeding. This is because large amounts of benzyl alcohol can build‑up in your body and may cause side effects (called “metabolic acidosis”).
Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build‑up in your body and may cause side effects (called “metabolic acidosis”).
3. How you are given Hemabate Sterile Solution
This product should be used only in hospitals and clinics with specialised units for pregnancy and childbirth. Medical staff should be available in the hospital at all times. Hemabate may be given by a doctor or a midwife.
The staff will make sure that this medicine is used in the right way and at the right time. You should never be given Hemabate while you are pregnant, only after the birth. It must never be given by injection into a vein.
- Hemabate is given by injection deep into a muscle.
- The first dose is usually 1 ml of solution (250 micrograms of carboprost). Your doctor may give you more doses of 1 ml if you need them. You should not have doses more often than once every 15 minutes. Usually you would have them less often, about once in one‑and‑a‑half hours.
- You should not be given more than 8 doses (2 mg of carboprost) altogether. Hemabate is not indicated for use in children.
If you are given more Hemabate than you should be
If you get very bad sickness and diarrhoea, your doctor may delay the next injection of Hemabate, or may not give you any more doses. Your doctor will treat the symptoms that the Hemabate has caused.
If you continue to bleed
If you continue to bleed heavily after being given Hemabate you may be given other medicines to help control the bleeding. Your doctor or midwife will be watching you PHYSICIAN LEAFLET
HEMABATE® Sterile Solution
(carboprost tromethamine)
Package Leaflet: Information for the patient
HEMABATE® Sterile Solution for Injection
carboprost tromethamine 250 mcg/ml
(perforation line) closely to help them decide whether Hemabate is working for you. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible Side Effects
Like all medicines, this medicine can cause side effects although not everybody gets them.
- Effects on your respiratory system and immune system: Hemabate can very occasionally cause serious breathing difficulties as well as asthma and wheezing. If you have any difficulty breathing after receiving Hemabate tell your doctor or midwife immediately.
- The benzyl alcohol in Hemabate solution can cause an allergic reaction in some people. If you suffer from wheezing together with any itching or swelling of the face or tongue tell your doctor or midwife immediately.
The following side effects are listed by frequency.
Very common: may affect more than 1 in 10 people.
These include: diarrhoea, nausea, vomiting, increased body temperature. Common: may affect up to 1 in 10 people.
These include: headache, flushing, hot flush, chills, coughing, bleeding from the uterus, retained placenta or membranes, and inflammation of the uterus.
Uncommon: may affect up to 1 in 100 people.
These include: septic shock, urinary tract infection, irregular sleep patterns or general feeling of drowsiness, dizziness, muscle contractions affecting your posture and positioning of the head, general muscle pain, pins and needles, abnormal taste, increased levels of sweating, chest discomfort, severe shortness of breath, asthma and
general breathing difficulties such as rapid breathing or wheezing, general pain especially in regions such as the upper abdomen, back and pelvis, tenderness of the breasts, blurred vision, eye pain, dry mouth, hiccups, vertigo, ringing in the ears, increased heart rate, high blood pressure, vomiting blood, uterine rupture, uterine cervical laceration, fluid retention, general feeling of being unwell and injection site pain. Not known: frequency cannot be estimated from the available data. These include: a rare but severe form of hyperthyroidism, anxiety, nervousness, fainting, temporary loss of consciousness caused by a fall in blood pressure, palpitations, muscle spasm in the walls of the bronchioles, swelling of the throat, choking sensation, nose bleeds, dry throat, infection affecting the nose sinuses and throat, retching, rash, muscle spasms, uncontrolled abnormal contraction or twitch of the eyelid, uterine disorder, chest pain, abnormal physical weakness or lack of energy, excessive thirst and hypersensitivity reactions (e.g. anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, angioedema).
Most effects are mild and short-lived and will wear off quickly after treatment.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Hemabate Sterile Solution
Keep this medicine out of the sight and reach of children.
Do not use Hemabate after the expiry date which is stated on the carton and on the ampoule after EXP. Your pharmacist will check this before the injection is given. The expiry date refers to the last day of the month.
Store in a refrigerator between 2 – 8°C. Your pharmacist will check the ampoules are still clear and colourless before use.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Hemabate contains
The active substance in each ampoule is 250 mcg of carboprost. The other ingredients are sodium chloride (sodium content approximately 4.0 mg/ml), water for injections, tromethamine and a preservative, benzyl alcohol (9.45 mg/ml). Small amounts of hydrochloric acid and sodium hydroxide, (used to regulate the acidity or alkalinity of the solution) may also be present.
What Hemabate looks like and contents of the pack
Hemabate is a colourless solution available in glass ampoules containing 1 ml of solution. Hemabate comes in packs of two or ten ampoules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Pfizer Limited
Ramsgate Road
Sandwich, Kent
CT13 9NJ
UK
Manufacturer
Pfizer Service Company BV
Hermeslaan 11
1932 Zaventem
Belgium
For more information about this medicine, please contact the local representative of the local Marketing Authorisation Holder: Medical Information
Pfizer Limited
Walton Oaks
Dorking Road
Tadworth
Surrey
KT20 7NS
UK
Telephone 01304 616161
This leaflet was last revised in 11/2025.
Ref: HM 11_0
Uncommon: may affect up to 1 in 100 people.
These include:
Septic shock, urinary tract infection, sleep disorder, syncope vasovagal, dizziness*, dystonia, paraesthesia, somnolence, dysgeusia, vision blurred, eye pain, vertigo, tinnitus, tachycardia, hypertension, asthma, respiratory distress, dyspnoea, hyperventilation*, wheezing, hiccups, haematemesis, upper abdominal pain, dry mouth, hyperhidrosis, torticollis, back pain, myalgia, uterine rupture, uterine cervical laceration, pelvic pain*, breast tenderness, lethargy, chest discomfort, injection site pain.
Not known: frequency cannot be estimated from the available data. Thyrotoxic crisis†, anxiety†, nervousness, syncope†, palpitations, bronchospasm, pharyngeal oedema†, choking sensation†, epistaxis†, dry throat, upper respiratory tract infection†, retching, rash†, muscle spasms, blepharospasm, uterine disorder, chest pain†, asthenia†, excessive thirst†, hypersensitivity reactions† (e.g. anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, angioedema).
* Events reported for both intramuscular and intra‑amniotic routes of administration are marked with an asterisk. All other events were reported only for the intramuscular route.
† Identified from post‑marketing experience.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdose
Treatment of overdosage must be symptomatic at this time, as clinical studies with prostaglandin antagonists have not progressed to the point where recommendations may be made.
If evidence of excessive side‑effects appears, the frequency of administration should be decreased or administration discontinued.
How to store Hemabate
Store in a refrigerator at 2 ‑ 8°C.
Legal category
POM
Package quantities
Pack containing 10 x 1 ml ampoules of Hemabate Sterile Solution 250 micrograms/ml.
Further information
Carboprost tromethamine stimulates the myometrium of the gravid uterus to contract in a manner that is similar to that observed in the term uterus during labour. Whether or not this action results from a direct effect of carboprost tromethamine on the myometrium has not been determined with certainty at this time.
When Hemabate is given post‑partum, the resulting myometrial contractions provide haemostasis at the site of placentation and hence prevent further blood loss.
Product licence number
PL 00057/1000
Marketing Authorisation Holder
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. Manufacturer
Pfizer Service Company BV, Hermeslaan 11, 1932 Zaventem, Belgium.
Date of Revision of the text
Ref: HM 11_0